52 Week Rng | - |
Market Cap | - |
Avg Volume | - |
1M Volatility | - |
Short Ratio | - |
P/E Ratio (TTM) | - |
P/E Ratio (Fwd) | - |
P/B Ratio | - |
Div & Yield | - |
aroundtheclock • Aalto Investment management game (Fall 2021) • Nov 2021
Health technology/ services sector. Relatively young company, lots of room for growth, price has been adjusted recently, low P/E
alpha_investors • Aalto Investment management game (Fall 2021) • Nov 2021
According to our strategy, this company has parameters of P/E < 15, small cap ($ 500 million - $ 2 billion), and a sector of healthcare.
business_investors • Aalto Investment Management Game (Fall 2020) • Nov 2020
Firm meets our low P/E value and market cap criteria, which are P/E < 15 and market cap between 300 million to 2 billion USD. Our fund is based on the passive value strategies. Firm is also based in the USA which will add geographic distribution. Healthcare sector is one of our fund's main sectors. The amount is based on our target leverage of 1.75 and target amount of different stocks.
profit_investors • Aalto Investment Management Game (Fall 2020) • Nov 2020
Firm meets our low P/E value and market cap criteria, which are P/E < 15 and market cap between 300m to 2b USD. Our fund is based on passive value strategy. Bigger return is pursued by riskier small cap firms and by using leverage. Firm is also based on USA which will add geographic distribution. Healthcare sector is one of our funds main sectors. Amount is based our target leverage of 1.8 :1 and target amount of different stocks.
TheMagicInvestors • Aalto Investment Management Game (Fall 2020) • Nov 2020
Twin factor value strategy (smart beta)| long position | equal weighting | stocks with the highest earnings yield and ROIC |
Jabadabaduu • OLD|Aalto Investment Management Game (Spring 2020) • Apr 2020
Automatic trade executed by Stockfuse to ensure margin compliance.
OR • OLD|Aalto Investment Management Game (Spring 2019) • Feb 2019
Closing position
Quant_Investors • OLD|Aalto Investment Management Game (Spring 2019) • Jan 2019
Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Profitable, growing, small cap and PE < 15.